Forte Biosciences, Inc.
Business
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related indications including celiac disease, vitiligo, alopecia areata, and type 1 diabetes. The company has completed Phase 1 trials in healthy volunteers and initiated patient-based Phase 1b trials; positive Phase 1b celiac disease data were announced in June 2025, with Phase 2 celiac disease trials underway. Forte outsources manufacturing to contract manufacturing organizations and clinical development to clinical research organizations, funded through equity offerings.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 58 | 21 | 22 | 6 | 14 | |
| Research and development - related party | 600,000 | 479,000 | — | — | — | |
| General and administrative | 12 | 15 | 11 | 8 | 8 | |
| Total operating expenses | 71 | 37 | 32 | 14 | 21 | |
| Loss from operations | −71 | −37 | −32 | −14 | −21 | |
| Interest income | 3 | 1 | 1 | 162,000 | — | |
| Other expense, net | −396,000 | −190,000 | −114,000 | −145,000 | −222,000 | |
| Total other income, net | 2 | 1 | — | — | — | |
| Net loss before taxes | −68 | −35 | — | — | — | |
| Income tax expense | 1 | 0 | — | — | — | |
| Net loss | −69 | −35 | −31 | −14 | −22 | |
| Net loss per share - basic | −4.71 | −12.17 | −24.92 | −0.8 | −1.55 | |
| Net loss per share - diluted | −4.71 | −12.17 | −24.92 | −0.8 | −1.55 | |
| Weighted average shares and pre-funded warrants outstanding, basic | 15 | 3 | 1 | 17 | — | |
| Weighted average shares and pre-funded warrants outstanding, diluted | 15 | 3 | 1 | 17 | — | |
| Unrealized (loss) gain on available-for-sale securities, net | −8,000 | 7,000 | 4,000 | — | — | |
| Comprehensive loss | −69 | −35 | −31 | −14 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 77 | 22 | 37 | 41 | 42 | |
| Short-term investments | — | 36 | — | — | — | |
| Prepaid expenses and other current assets | 4 | 3 | 1 | 411,000 | 476,000 | |
| Total current assets | 81 | 61 | 38 | 42 | 43 | |
| Property and equipment, net | 129,000 | 77,000 | 109,000 | — | — | |
| Other assets | 2 | 138,000 | 544,000 | 486,000 | 786,000 | |
| Total assets | 83 | 62 | 39 | 42 | 43 | |
| Accounts payable | 10 | 5 | 1 | 1 | 946,000 | |
| Accrued liabilities | 11 | 4 | 2 | 2 | 812,000 | |
| Total current liabilities | 21 | 9 | 4 | 3 | 2 | |
| Income tax payable | 1 | — | — | — | — | |
| Total liabilities | 22 | 9 | — | — | — | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Common stock, $0.001 par value: 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 12,948,308 and 6,393,323 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 13,000 | 6,000 | 1,000 | 21,000 | 15,000 | |
| Additional paid-in capital | 284 | 206 | 154 | 126 | 115 | |
| Accumulated other comprehensive income | 3,000 | 11,000 | 4,000 | — | — | |
| Accumulated deficit | −223 | −154 | −119 | −87 | −73 | |
| Total stockholders equity | 61 | 52 | 35 | 39 | 42 | |
| Total liabilities and stockholders' equity | 83 | 62 | 39 | 42 | 43 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −69 | −35 | — | — | — | |
| Depreciation expense | 64,000 | 39,000 | 9,000 | — | 36,000 | |
| Accretion of debt discount on available-for-sale securities | −237,000 | −158,000 | −131,000 | — | — | |
| Stock-based compensation expense | 6 | 3 | 3 | 4 | 4 | |
| Prepaid expenses and other assets | −3 | −1 | −849,000 | 258,000 | 1 | |
| Accounts payable | 6 | 3 | 271,000 | 207,000 | −294,000 | |
| Accrued liabilities | 8 | 109,000 | 186,000 | 1 | −207,000 | |
| Income taxes payable | 1 | 0 | — | — | — | |
| Net cash used in operating activities | −51 | −31 | −29 | −8 | −17 | |
| Purchase of available-for-sale securities | 0 | −36 | −10 | — | — | |
| Proceeds from redemptions of short-term investments | 36 | 0 | — | — | — | |
| Purchase of property and equipment | −116,000 | −37,000 | −88,000 | — | — | |
| Net cash provided by (used in) investing activities | 36 | −36 | 47,000 | — | — | |
| Proceeds from issuance of common stock and pre-funded warrants | 75 | 53 | 25 | 7 | — | |
| Payment of issuance costs associated with financings | −7 | −1 | −272,000 | — | −106,000 | |
| Proceeds from issuance of common stock upon exercise of underwriters' option | 2 | 0 | — | 7 | — | |
| Proceeds from issuance of common stock under ESPP | 18,000 | 14,000 | — | — | — | |
| Proceeds from exercise of warrants and options | 34,000 | 0 | — | — | — | |
| Taxes paid related to net share settlement of equity awards | −29,000 | −35,000 | −60,000 | — | — | |
| Settlement of fractional shares paid in cash | 0 | −1,000 | — | — | — | |
| Net cash provided by financing activities | 69 | 52 | 25 | 7 | −44,000 | |
| Net increase (decrease) in cash and cash equivalents | 55 | −15 | −4 | −944,000 | −17 | |
| Unpaid issuance costs recorded in accounts payable and accrued liabilities | 41,000 | 2 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Forte Biosciences, Inc.'s CIK number?
Forte Biosciences, Inc.'s SEC CIK number is 0001419041 (1419041). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Forte Biosciences, Inc.'s SEC filings?
All of Forte Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Forte Biosciences, Inc. last report earnings?
Forte Biosciences, Inc. (FBRX) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-224214). This is Forte Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Forte Biosciences, Inc.'s most recent earnings 8-K?
Forte Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-224214. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Forte Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →